← Leaderboards
Benjamin J Drapkin
Ut Southwestern Medical Center
$1,876,819
Attributed
$1,876,819
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $642.4K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,876,819 · 2
By mechanism
K08$1,234,390 · 1
R01$642,429 · 1
Top collaborators
No co-investigators on record.
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Philipp E Scherer$40,932,820
- Bruce A Beutler$69,298,220
- Eric N Olson$45,475,240
- Diego H Castrillon$18,503,509
- Michael Kyba$19,625,267
Others in their field
Other Emerging Leaders on “Relapse”
- Andrew S Huhn · Johns Hopkins University$14,832,590
- Nikej Shah · Nirsum Laboratories, Inc.$12,506,430
- Gonul Velicelebi · Sanford Burnham Prebys Medical Discovery Institute$8,970,452
- Gary Fanger · Rise Therapeutics, Llc$8,202,376
- Geoffrey Roger Hill · Fred Hutchinson Cancer Center$6,841,955
- Jeffrey Benner · Drug Delivery Company, Llc, The$6,616,062
Research focus
RelapseSamplingMolecularRegimenResistance MechanismResponseHeterogeneityMalignant NeoplasmsGenesPharmaceutical PreparationsExperimental StudyResistanceBiopsy SpecimenChemotherapyBiological MarkersDna DamageDiagnosisInvestigational TherapiesClinical TrialsCancer PatientNeoplasm Circulating CellsPatient ResponseBiological ModelsTumor
Grant awards (6)
Acquired Cross-Resistance through MYC Amplification in Small Cell Lung Cancer$642,429
R01 · FY2025 · CA · contact PI
Dissecting and overcoming cross-resistance to DNA damaging agents in SCLC$246,878
K08 · FY2024 · CA · contact PI
Dissecting and overcoming cross-resistance to DNA damaging agents in SCLC$246,878
K08 · FY2023 · CA · contact PI
Dissecting and overcoming cross-resistance to DNA damaging agents in SCLC$246,878
K08 · FY2022 · CA · contact PI
Dissecting and overcoming cross-resistance to DNA damaging agents in SCLC$246,878
K08 · FY2021 · CA · contact PI
Dissecting and overcoming cross-resistance to DNA damaging agents in SCLC$246,878
K08 · FY2020 · CA · contact PI